Market Overview

Integra Lifesciences Wins CE Mark Certification for Flowable Wound Matrix

Related IART
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Benzinga's Top Upgrades, Downgrades For April 5, 2018

Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that it has received European CE Mark Certification for its Integra^® Flowable Wound Matrix, an advanced device approved in the European Union for filling deep soft tissue or tunneling wounds, including diabetic foot and leg ulcers.

The Société Française de Chirurgie Plastique Reconstructrice et Esthétique (SOF.CPRE) (French Society of Reconstructive and Esthetic Plastic Surgery), one of Europe's pre-eminent medical associations, has also awarded Integra's Flowable Wound Matrix 1^st place in its innovation contest. Each year, over 1,000 surgeons attend the annual meeting and are asked to vote on the most innovative new product, based on its performance. This year, the majority of the voters selected Integra's Flowable Wound Matrix. 

Posted-In: News


Related Articles (IART)

View Comments and Join the Discussion!